Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics
ACRS Price/Volume Stats
| Current price | $1.15 | 52-week high | $11.12 |
| Prev. close | $1.17 | 52-week low | $0.59 |
| Day low | $1.15 | Volume | 271,564 |
| Day high | $1.20 | Avg. volume | 1,494,579 |
| 50-day MA | $1.22 | Dividend yield | N/A |
| 200-day MA | $3.82 | Market Cap | 81.56M |
ACRS Stock Price Chart Interactive Chart >
Aclaris Therapeutics, Inc. (ACRS) Company Bio
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.
Latest ACRS News From Around the Web
Below are the latest news stories about ACLARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate ACRS as an investment opportunity.
Aclaris Therapeutics Provides Corporate Update- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates. First, Aclaris announced the publication of the Phase 2a trial results of ATI-17 |
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaWAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitini |
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis StudyAclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news. |
ACRS Price Returns
| 1-mo | -2.54% |
| 3-mo | -6.50% |
| 6-mo | -73.98% |
| 1-year | -87.06% |
| 3-year | -95.59% |
| 5-year | -83.71% |
| YTD | 9.52% |
| 2023 | -93.33% |
| 2022 | 8.32% |
| 2021 | 124.73% |
| 2020 | 242.33% |
| 2019 | -74.42% |
Continue Researching ACRS
Want to see what other sources are saying about Aclaris Therapeutics Inc's financials and stock price? Try the links below:Aclaris Therapeutics Inc (ACRS) Stock Price | Nasdaq
Aclaris Therapeutics Inc (ACRS) Stock Quote, History and News - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...